Bayer loses first trial on Xarelto safety risks in U.S.Bayer and Janssen have lost their first case in a series of U.S. trials over their failure to warn of internal bleeding risks with anticoagulant Xarelto (rivaroxaban) (APMHE 55936), Handelsblatt (p19) and the Frankfurter Allgemeine Zeitung (FAZ) reported on Thursday (p25).
Sanofi's dengue vaccine under investigation in the PhilippinesThe Philippines has ordered Sanofi to stop the sale of its Dengvaxia dengue vaccine and has launched an investigation, reported Handelsblatt (p22) on Tuesday and Sueddeutsche Zeitung (SZ) (p16) and Die Welt (p10) on Wednesday. (APMHE 55897)
Bayer/Monsanto takeover makes progress in U.S.Bayer's $66 billion takeover of U.S. seeds giant Monsanto has been cleared by the committee on foreign investment in the U.S. (CFIUS) (APMHE 55859), FAZ reported on Saturday (p26).
Deadline approaches for offers for Merck KGaA's OTC divisionPurchase offers for Merck KGaA's non-prescription drugs division should be submitted by December 15, writes Wirtschafts Woche on Friday (p46-48).
Bayer eyes non-organic growth opportunities in cancerBayer intendeds to supplement its proprietary cancer research with purchases of active ingredients from outside businesses, FAZ reported on Saturday (p26).
Monoclonal antibodies may be useful against migraineMonoclonal antibodies such as Sanofi/Amgen's erenumab and Teva's fremanezumab showed positive Phase III results in the prevention of migraine, reported FAZ on Wednesday (p37).
Regulatory know-how gives big pharma edge over tech - Merck KGaADeep knowledge of drug regulation and experience with payers give pharma the edge over tech companies in the race to be the next-generation suppliers of medicine, Merck KGaA CEO Stefan Oschmann said in an interview with FAZ published on Sunday (p27).
German pharmacists fear planned CVS/Aetna mergerThe $69 billion planned merger between U.S. pharmacy CVS and health insurer Aetna is fuelling fears in Germany that a new wave of mergers will bring Amazon into the pharmaceutical market, Die Welt reported on Wednesday (p12).
Statutory payers under investigation for fraudThe Hamburg public prosecutor's office has been investigating fraud allegedly committed by several statutory healthcare payers including AOK Rhineland/Hamburg for over a year, Die Welt reported on Monday (p10).
Citizens' insurance programme not worth the effortOne potential consequence of another grand coalition in Germany between the conservative (CDU) party and the social democrats (SPD) is the formation of a "citizens insurance" in Germany to replace the current statutory and private insurance schemes, SZ (p17) and Die Welt (p2) reported on Tuesday.
'Wise decision-making' needed in antibiotic prescribing"Wise decision making" as espoused by the German Society for Internal Medicine and "thinking twice" as encouraged by the WHO in recent PR campaigns are what is necessary to curb unnecessary antibiotic use, SZ reported on Tuesday (p2).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.